OSE Immuno Stock (OSE.PA): Analysis & Outlook

OSE Immuno Stock: Real-Time Share Price of ()

Right now, you can buy OSE Immuno stock () at a price of per share. Since the start of the trading day, the share price has moved by %.

At the open, the share price was . During the session, the highest level reached by the share price was , while the lowest was , and today’s closing price is .

Is OSE Immuno a Good Investment? Key Figures

Over the past year (trailing 52 weeks), the share price peaked at , and the lowest level reached over these last 52 weeks was .

Ouvrir un compte Vantage →

Over the last 5 trading sessions, the OSE.PA share price of () has moved as follows:

Should You Buy Stock?

Currently, the share price stands at and pays a dividend of per share! The dividend yield is % per year if you buy shares at the current price.

Also consider choosing a broker that has the advantage of offering a comprehensive solution to buy stocks from all over the world! This will allow you to diversify your portfolio later on.

Analyst Consensus and Price Target for Stock

Stock Dividend

The Shareholders of

Here are the current shareholders of :

• Emile Loria – 12.17%
• Dominique Constantini – 9.221%
• Alexis Peyroles – 4.272%
• Maryvonne Hiance – 1.948%
• Mandarine Gestion SA – 1.057%
• Nicolas Poirier – 0.8857%
• Saint Olive Gestion SNC – 0.5513%
• La Française Asset Management SAS – 0.5053%
• Claresco Finance SA – 0.1424%

Competitors of

While direct competitors may vary depending on specialization and geographic reach, here are some companies that could be considered potential competitors of :

• Biotechnology companies specializing in immunotherapy: Companies such as Bristol Myers Squibb (Buy Bristol Myers Squibb stock), Merck & Co., Inc. (Buy Merck stock) and Regeneron Pharmaceuticals (Buy Regeneron Pharmaceuticals stock) are leaders in the development and commercialization of immunotherapy treatments for cancer and other diseases.
• Large pharmaceutical companies: Major pharmaceutical companies such as Roche (Buy Roche stock), Novartis (Buy Novartis stock), Pfizer (Buy Pfizer stock) and AstraZeneca (Buy AstraZeneca stock) also invest in the research and development of immunotherapies and can be considered potential competitors.
• Startups and emerging biotech companies: There are many startups and emerging biotech companies focused on developing immunotherapy treatments. Some of these companies may compete directly with OSE Immunotherapeutics in specific therapeutic areas or with similar technological approaches.
• Universities and research institutes: While not direct competitors in the market, universities and research institutes play a crucial role in developing new immunotherapy technologies and treatments. They can also be potential partners or sources of indirect competition.
• Other biopharmaceutical companies: Depending on specific products and indications, OSE Immunotherapeutics may also compete with other biopharmaceutical companies developing treatments for the same type of cancer or autoimmune disease.

It is important to note that competition in the biopharmaceutical industry is dynamic and can evolve quickly depending on scientific advances, clinical trial results, and the commercial strategies of companies.

Clients of the Company

As a biopharmaceutical company specializing in the development of immunotherapy treatments, OSE Immunotherapeutics has no traditional customers in the commercial sense. Instead, it interacts with several key stakeholders in the pharmaceutical and medical ecosystem, including:

• Patients and healthcare professionals: Patients and healthcare professionals are the main beneficiaries of the therapies developed by OSE Immunotherapeutics. Doctors prescribe and administer these therapies to treat the targeted diseases, such as cancer and autoimmune diseases.
• Research and development partners: OSE Immunotherapeutics can collaborate with other biopharmaceutical companies, academic institutions, and research organizations to develop and test new therapies, exchange technologies, or share resources.
• Investors and shareholders: The investors and shareholders of the company provide the funds that support the research, development, and commercial operations of OSE Immunotherapeutics. They have a financial interest in the success of the company.
• Regulatory bodies: Regulatory authorities, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe, oversee the drug approval process. OSE Immunotherapeutics interacts with these bodies to obtain regulatory approval for its products.
• Commercial partners and potential distributors: Once the therapies of OSE Immunotherapeutics are approved and available on the market, the company can work with commercial partners and distributors to market and distribute its products around the world.

These examples are not exhaustive, and the list of clients of may vary depending on its commercial strategy and growth initiatives.

Why Invest in Stock

Investing in OSE Immunotherapeutics stock, one of the Paris-listed immuno oncology stocks, can be an interesting decision for several reasons:

• Innovative technology: OSE Immunotherapeutics specializes in developing innovative immunotherapy treatments for cancer and autoimmune diseases. Investing in a company focused on the research and development of cutting-edge medical technologies can offer significant growth potential.
• Promising pipeline: The OSE Immuno pipeline is diversified, comprising several promising drug candidates at different stages of clinical development. The potential success of any of these candidates could have a positive impact on the stock value.
• Unmet medical need: Treatments for cancer and autoimmune diseases remain areas where unmet medical needs still exist. The therapies developed by OSE Immunotherapeutics aim to address these needs, and progress in OSE Immuno clinical trials could translate into growing demand for its products.
• Strategic collaborations: OSE Immunotherapeutics has established strategic partnerships with other pharmaceutical companies and research institutions, which can bring additional funding, development opportunities, and external validation of its technologies and products.
• Financial performance: While past performance does not guarantee future results, a careful analysis of the company’s financial statements can help investors assess its financial strength and growth potential.

Investing in a specific stock like requires thorough research and an understanding of the risks and opportunities associated with this particular company.

You can invest in OSE Immuno stock on the Euronext Paris market, alongside other French biotech stocks (Euronext Exchange).

This article is for educational purposes and does not constitute investment advice. The investments mentioned carry a risk of capital loss.